Jorda R - Search Results

1

Design, Synthesis, In Silico Studies and Inhibitory Activity towards Bcr-Abl, BTK and FLT3-ITD of New 2,6,9-Trisubstituted Purine Derivatives as Potential Agents for the Treatment of Leukaemia.

Bertrand J, Dostálová H, Kryštof V, Jorda R, Delgado T, Castro-Alvarez A, Mella J, Cabezas D, Faúndez M, Espinosa-Bustos C, Salas CO. Bertrand J, et al. Among authors: jorda r. Pharmaceutics. 2022 Jun 17;14(6):1294. doi: 10.3390/pharmaceutics14061294. Pharmaceutics. 2022. PMID: 35745866 Free PMC article.

2

Functional p53 in cells contributes to the anticancer effect of the cyclin-dependent kinase inhibitor roscovitine.

Paprskárová M, Krystof V, Jorda R, Dzubák P, Hajdúch M, Wesierska-Gadek J, Strnad M. Paprskárová M, et al. Among authors: jorda r. J Cell Biochem. 2009 Jun 1;107(3):428-37. doi: 10.1002/jcb.22139. J Cell Biochem. 2009. PMID: 19308936

3

Pharmacological targeting of CDK9 in cardiac hypertrophy.

Krystof V, Chamrád I, Jorda R, Kohoutek J. Krystof V, et al. Among authors: jorda r. Med Res Rev. 2010 Jul;30(4):646-66. doi: 10.1002/med.20172. Med Res Rev. 2010. PMID: 19757441 Review.

4

Pyrazolo[4,3-d]pyrimidine bioisostere of roscovitine: evaluation of a novel selective inhibitor of cyclin-dependent kinases with antiproliferative activity.

Jorda R, Havlícek L, McNae IW, Walkinshaw MD, Voller J, Sturc A, Navrátilová J, Kuzma M, Mistrík M, Bártek J, Strnad M, Krystof V. Jorda R, et al. J Med Chem. 2011 Apr 28;54(8):2980-93. doi: 10.1021/jm200064p. Epub 2011 Apr 6. J Med Chem. 2011. PMID: 21417417

5

Anti-leishmanial activity of disubstituted purines and related pyrazolo[4,3-d]pyrimidines.

Jorda R, Sacerdoti-Sierra N, Voller J, Havlíček L, Kráčalíková K, Nowicki MW, Nasereddin A, Kryštof V, Strnad M, Walkinshaw MD, Jaffe CL. Jorda R, et al. Bioorg Med Chem Lett. 2011 Jul 15;21(14):4233-7. doi: 10.1016/j.bmcl.2011.05.076. Epub 2011 May 27. Bioorg Med Chem Lett. 2011. PMID: 21683592

6

The selective P-TEFb inhibitor CAN508 targets angiogenesis.

Kryštof V, Rárová L, Liebl J, Zahler S, Jorda R, Voller J, Cankař P. Kryštof V, et al. Among authors: jorda r. Eur J Med Chem. 2011 Sep;46(9):4289-94. doi: 10.1016/j.ejmech.2011.06.035. Epub 2011 Jul 3. Eur J Med Chem. 2011. PMID: 21777997

7

Cyclin-dependent kinase inhibitors inspired by roscovitine: purine bioisosteres.

Jorda R, Paruch K, Krystof V. Jorda R, et al. Curr Pharm Des. 2012;18(20):2974-80. doi: 10.2174/138161212800672804. Curr Pharm Des. 2012. PMID: 22571665 Review.

8

Synthesis and in vitro biological evaluation of 2,6,9-trisubstituted purines targeting multiple cyclin-dependent kinases.

Zatloukal M, Jorda R, Gucký T, Řezníčková E, Voller J, Pospíšil T, Malínková V, Adamcová H, Kryštof V, Strnad M. Zatloukal M, et al. Among authors: jorda r. Eur J Med Chem. 2013 Mar;61:61-72. doi: 10.1016/j.ejmech.2012.06.036. Epub 2012 Jun 23. Eur J Med Chem. 2013. PMID: 22770608

9

A novel series of highly potent 2,6,9-trisubstituted purine cyclin-dependent kinase inhibitors.

Gucký T, Jorda R, Zatloukal M, Bazgier V, Berka K, Řezníčková E, Béres T, Strnad M, Kryštof V. Gucký T, et al. Among authors: jorda r. J Med Chem. 2013 Aug 8;56(15):6234-47. doi: 10.1021/jm4006884. Epub 2013 Jul 24. J Med Chem. 2013. PMID: 23829517

10

Arylazopyrazole AAP1742 inhibits CDKs and induces apoptosis in multiple myeloma cells via Mcl-1 downregulation.

Jorda R, Navrátilová J, Hušková Z, Schütznerová E, Cankař P, Strnad M, Kryštof V. Jorda R, et al. Chem Biol Drug Des. 2014 Oct;84(4):402-8. doi: 10.1111/cbdd.12330. Epub 2014 May 12. Chem Biol Drug Des. 2014. PMID: 24803299

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

97 results

Search Page